Skip to content

Ibogaine: all studies

Page 34 of 62: studies 331 to 340 of 613, newest first. Back to the ibogaine overview

Research

Ibogaine and the dopaminergic response to nicotine.

Psychopharmacology February 1, 1997 Isabelle M Maisonneuve, G L Mann, C R Deibel et al. 38 citations

There is increasing evidence that the rewarding effect of nicotine is mediated by the mesolimbic dopamine system. The first objective of this study was to examine the dopamine response to repeated i.v. infusions of nicotine. Using in vivo microdialysis in awake and freely moving male Sprague-Dawley rats, we demonstrated that i.v. nicotine infusions (0.16 mg/kg or 0.32 mg/kg per infusion)...

Ibogaine and cocaine abuse: pharmacological interactions at dopamine and serotonin receptors.

Brain Research Bulletin 1997 Henry Sershen, Audrey Hashim, Ábel Lajtha 32 citations

Ibogaine is an indole alkaloid that has been of interest in recent years due to its putative efficacy in the treatment of drug dependence. For the most part, animal data have shown attenuation of some of the effects of stimulant drugs, for example, motor stimulation and self-administration. The mechanism of this inhibition of drug-induced behavior seems to suggest the action of the dopamine,...

Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors.

Molecular Pharmacology 1997 B Badio, W L Padgett, J W Daly 52 citations

Ibogaine noncompetitively blocked (IC50 approximately 20 nM) 22NaCl influx through ganglionic-type nicotinic receptor channels of rat pheochromocytoma PC12 cells. The major metabolite O-des-methylibogaine was 75-fold less active, and O-t-butyl-O-des-methylibogaine was 20-fold less active. Ibogaine was relatively weak as a blocker (IC50 approximately 2000 nM) of the neuromuscular-type nicotinic...

The effects of noribogaine and harmaline in rats trained with ibogaine as a discriminative stimulus.

Life Sciences 1997 Scott Helsley, R A Rabin, Jerrold C Winter 13 citations

In the present investigation, Fischer-344 rats were trained to discriminate 10.0 mg/kg of ibogaine from water using a pretreatment time of 60 minutes. Analysis of dose response data generated an ED50 of 4.6 mg/kg. The time course of the ibogaine (10.0 mg/kg) cue was also determined. The stimulus reached a maximum level of 94% ibogaine-appropriate responding at the 60-min pretreatment time. This...

Ibogaine and a total alkaloidal extract of Voacanga africana modulate neuronal excitability and synaptic transmission in the rat parabrachial nucleus in vitro.

Brain Research Bulletin 1997 S B Kombian, T M Saleh, N I Fiagbe et al. 14 citations

Ibogaine is a natural alkaloid of Voacanga africana that is effective in the treatment of withdrawal symptoms and craving in drug addicts. As the synaptic and cellular basis of ibogaine's actions are not well understood, this study tested the hypothesis that ibogaine and Voacanga africana extract modulate neuronal excitability and synaptic transmission in the parabrachial nucleus using the...

Ibogaine selectively inhibits nicotinic receptor-mediated catecholamine release.

European Journal of Pharmacology December 19, 1996 A S Schneider, J E Nagel, S J Mah 20 citations

The effects of ibogaine, a putative anti-addictive drug, on stimulated catecholamine release were examined in cultured chromaffin cells to clarify its mechanism(s) of action. Low concentrations of ibogaine (1-10 microM) had a selective inhibitory action on nicotinic receptor-mediated catecholamine release, while higher concentrations (100 microM) inhibited additional modes of stimulated...

Ibogaine and noribogaine potentiate the inhibition of adenylyl cyclase activity by opioid and 5-HT receptors.

European Journal of Pharmacology December 5, 1996 R A Rabin, Jerrold C Winter 17 citations

The effects of the putative anti-addictive compound ibogaine and its principal metabolite, noribogaine, on adenylyl cyclase activity were determined in various areas of the rat brain. Neither compound altered either basal or forskolin-stimulated adenylyl cyclase activities in the frontal cortex, midbrain or striatum. However, in all three brain areas the addition of ibogaine and noribogaine...

Modulation of morphine-induced antinociception by ibogaine and noribogaine.

Brain Research November 25, 1996 A A Bagal, L B Hough, J W Nalwalk et al. 23 citations

The potential modulation of morphine antinociception by the putative anti-addictive agent ibogaine and its active metabolite (noribogaine) was investigated in rats with the radiant heat tail-flick test. Ibogaine pretreatment (40 mg/kg, i.p., 19 h) significantly decreased morphine (4 mg/kg, s.c.) antinociception, with no effects in the absence of morphine. However, co-administration of ibogaine...

Acute and chronic administration of ibogaine to the rat results in astrogliosis that is not confined to the cerebellar vermis.

Annals of the New York Academy of Sciences October 31, 1996 J P O'Callaghan, T S Rogers, L E Rodman et al. 14 citations

Acute administration of high doses of ibogaine (IBG) to the male rat results in degeneration of Purkinje cells and reactive gliosis in the cerebellar vermis. We examined whether acute and chronic administration of IBG to male and female rats results in gliosis as determined by quantification of the astroglial intermediate filament protein, glial fibrillary acidic protein (GFAP). After acute...

Neuroendocrine and neurochemical effects of acute ibogaine administration: a time course evaluation.

Brain Research October 21, 1996 S F Ali, Glenn D. Newport, William Slikker et al. 29 citations

Ibogaine (IBO) is an indole alkaloid that is reported to facilitate drug abstinence in substance abusers. Despite considerable investigation, the mechanism of IBO action in vivo and its suitability as a treatment for drug addiction remains unclear. The present study was designed to evaluate the time-course effects of acute IBO on neuroendocrine and neurochemical indices. Adult male rats were...